Literature DB >> 2925242

Protective efficacy of protein A-specific antibody against bacteremic infection due to Staphylococcus aureus in an infant rat model.

D P Greenberg1, A S Bayer, A L Cheung, J I Ward.   

Abstract

Staphylococcal protein A (SpA) is a potent antiphagocytic component of the cell wall of most pathogenic Staphylococcus aureus strains. We studied the in vitro opsonophagocytic and in vivo protective activities of rabbit immunoglobulin G (IgG) antibody to purified SpA obtained from two unencapsulated S. aureus strains (Cowan I and 17A). Postimmune serum contained high titers of specific IgG to SpA, as measured by a modified enzyme-linked immunosorbent assay that blocked nonspecific binding of IgG to SpA. In vitro, both S. aureus strains were efficiently phagocytosed and killed by polymorphonuclear leukocytes in the presence of nonimmune sera and complement. With one strain (Cowan I), opsonophagocytosis was significantly enhanced in the presence of SpA antibody, but with the other strain (17A), killing was significantly decreased with immune serum. We then evaluated the potential protective benefit of SpA antibody in preventing S. aureus bacteremia in infant rats. Two-day-old rats received saline or various doses of SpA antiserum and were challenged subcutaneously 1 day later, but even the highest levels of antibody did not significantly reduce mortality, bacteremia or metastatic infection to lungs or liver (frequency or magnitude). This lack of protective efficacy was not related to a failure of SpA F(ab')2 to bind to cell surface-exposed epitopes, since F(ab')2 fragments prepared from hyperimmune serum bound avidly to the whole organism in an enzyme-linked immunosorbent assay.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925242      PMCID: PMC313238          DOI: 10.1128/iai.57.4.1113-1118.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  STUDIES ON HEAT-LABILE OPSONIN IN RABBIT SERUM.

Authors:  J G HIRSCH; B STRAUSS
Journal:  J Immunol       Date:  1964-01       Impact factor: 5.422

2.  Surface proteins of Staphylococcus aureus.

Authors:  A L Cheung; A S Bayer; J Peter; J I Ward
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

3.  Protein A from Staphylococcus aureus. IX. Complement-fixing activity of protein A-IgG complexes.

Authors:  J Sjöquist; G Stålenheim
Journal:  J Immunol       Date:  1969-09       Impact factor: 5.422

4.  Serological diagnosis of deep Staphylococcus aureus infections by enzyme-linked immunosorbent assay (ELISA) for staphylococcal hemolysins and teichoic acid.

Authors:  M Granström; I Julander; R Möllby
Journal:  Scand J Infect Dis Suppl       Date:  1983

5.  A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies.

Authors:  W D Zollinger; J W Boslego
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

6.  Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts.

Authors:  H F Chambers; O M Korzeniowski; M A Sande
Journal:  Medicine (Baltimore)       Date:  1983-05       Impact factor: 1.889

7.  Clinical value of teichoic acid antibody titers in the diagnosis and management of the staphylococcemias.

Authors:  A S Bayer; D B Tillman; N Concepcion; L B Guze
Journal:  West J Med       Date:  1980-04

8.  Protein A from Staphylococcus aureus. 8. Production of protein A by bacterial and L-forms of S. aureus.

Authors:  A Forsgren
Journal:  Acta Pathol Microbiol Scand       Date:  1969

9.  Staphylococcus aureus endocarditis. A review of 119 cases.

Authors:  F Espersen; N Frimodt-Møller
Journal:  Arch Intern Med       Date:  1986-06

10.  Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum.

Authors:  P A Rice; H E Vayo; M R Tam; M S Blake
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  13 in total

1.  Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis.

Authors:  E B Hume; J J Dajcs; J M Moreau; R J O'Callaghan
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 2.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Heparin stimulates Staphylococcus aureus biofilm formation.

Authors:  Robert M Q Shanks; Niles P Donegan; Martha L Graber; Sarah E Buckingham; Michael E Zegans; Ambrose L Cheung; George A O'Toole
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Regulation of protein A synthesis by the sar and agr loci of Staphylococcus aureus.

Authors:  A L Cheung; K Eberhardt; J H Heinrichs
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Role of the sar locus of Staphylococcus aureus in induction of endocarditis in rabbits.

Authors:  A L Cheung; M R Yeaman; P M Sullam; M D Witt; A S Bayer
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen.

Authors:  Michael D Raedler; Samantha Heyne; Erica Wagner; Sheri K Shalkowski; Susan Secore; Annaliesa S Anderson; James Cook; Leslie Cope; Tessie McNeely; Mary Retzlaff; Jon Shanter; Leonard J Rubinstein; Tina Green; N Kartsonis; Mark T Esser
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

7.  Antibody responses to protein A in patients with Staphylococcus aureus bacteremia and endocarditis.

Authors:  D P Greenberg; A S Bayer; D Turner; J I Ward
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

8.  Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.

Authors:  J Nemeth; J C Lee
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus.

Authors:  Eva Glowalla; Bettina Tosetti; Martin Krönke; Oleg Krut
Journal:  Infect Immun       Date:  2009-04-13       Impact factor: 3.441

10.  Closed trauma, Mycoplasma hominis osteomyelitis, and the elusive diagnosis of Good's syndrome.

Authors:  Amanda Noska; Rawad Nasr; David Neville Williams
Journal:  BMJ Case Rep       Date:  2012-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.